Data Foundry

Drug recalls 2025

Budesonide Inhalation Suspension — Class II drug recall D-0541-2025

Ongoing recall by Cipla USA, Inc., reported 2025-07-30, distributed nationwide. Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

Recall numberD-0541-2025
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmCipla USA, Inc., Warren, NJ, United States
Recall initiated2025-06-30
Classified2025-07-22
Reported by FDA2025-07-30
DistributedNationwide (US)
Quantity13,680 ampules
Reason classessterility, packaging
NDC69097-0318, 69097-0318-32, 69097-0318-53, 69097-0318-86, 69097-0318-87, 69097-0319, 69097-0319-32, 69097-0319-53, 69097-0319-86, 69097-0319-87, 69097-0321, 69097-0321-32, 69097-0321-53, 69097-0321-86, 69097-0321-87
Lot numbers4IA0505

Product

Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured by: Cipla Ltd. Indore SEZ, Pithampur, India. Manufactured for: Ciple USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC# 69097-319-86 (pouch), 69097-319-87 (carton)

Reason for recall

Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0541-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.